Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 (iPROACT-pilot2)

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this trial is to investigate the biological effects of oral supplementation with indole-3-propionic acid (IPA) taken twice daily in healthy adults. The main scientific questions are: * Does supplementation with IPA increase the abundance of regulatory T cells in the blood? Regulatory T cells are believed to play an important role in preventing autoimmune diseases. * Does supplementation with IPA increase the concentration of brain-derived neurotrophic factor (BDNF) in the blood? BDNF is believed to play an important role in maintaining brain health. * Does supplementation with IPA affect blood analyses commonly performed to assess the risk of metabolic disorders like type 2 diabetes and cardiovascular diseases? Participants will: * Take capsules to achieve a total daily dose of 1000 mg of IPA or placebo: 500 mg every morning and 500 mg every evening for 14 days. * Visit the clinic at the beginning (day 1) and at the end (day 15) of the supplementation period to deliver blood, urine and fecal samples, have simple measurements performed, fulfil questionnaires and report any side effects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Healthy women and men ≥18 and ≤65 years of age

• Deemed mentally and physically able to participate

Locations
Other Locations
Denmark
Optic Neuritis Clinic, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup
RECRUITING
Glostrup Municipality
Contact Information
Primary
Moschoula Passali, MSc, PhD
moschoula.passali@regionh.dk
+45 38633467
Time Frame
Start Date: 2025-08-04
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 32
Treatments
Placebo_comparator: Placebo
Placebo
Experimental: Indole-3-propionic acid (IPA)
IPA: total daily dose of 1000 mg
Related Therapeutic Areas
Sponsors
Collaborators: University of Copenhagen, University of Southampton
Leads: Glostrup University Hospital, Copenhagen

This content was sourced from clinicaltrials.gov